NASDAQ: KYNB · Life Sciences · 3 alerts · CIK 921299
Share price
$3.20Close, Nov 16
Market cap
$13M
Shares outstanding
4.05MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kyntra Bio, Inc. filings on SEC EDGAR ↗
Kyntra Bio reported Q3 2026 financial results, highlighting a cash position of $44.1 million and a runway extended into 2028. The company announced the discontinuation of its FG-3246 and FG-3180 programs due to insufficient efficacy, shifting focus toward a planned Phase 3 trial for roxadustat in early 2027. Additionally, the company restructured a royalty financing agreement, reducing its maximum payment obligation by $60 million.
Term
Q3 2026
“Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial. We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial.”
Thane Wettig, Chief Executive Officer of Kyntra Bio
Kyntra Bio received a delisting determination from Nasdaq on September 30, 2026, for failing to meet the minimum total assets and revenue requirements under Listing Rule 5450(b). The company has requested a hearing before a Nasdaq Hearings Panel to seek an extension, which stays the suspension of its common stock pending a decision. Kyntra Bio is preparing a compliance plan but cannot guarantee the Panel will grant the request for continued listing.
Kyntra Bio appointed Andrew E. Singer to its Board of Directors and Audit Committee, effective October 1, 2026. Simultaneously, Maykin Ho, Ph.D. resigned from the Board after nearly eight years of service. The company also renewed a change-in-control and severance agreement with CEO Thane Wettig for a three-year term with no material changes to compensation.